Education
About Us
Working with TipRanks
Follow Us
Sandoz Group Ltd Sponsored ADR (SDZNY)
OTHER OTC:SDZNY
Top Page
Sandoz Group Ltd Sponsored ADR
(OTC:SDZNY)
Select Model
Select Model
Rating:64Neutral
Price Target:
$88.00
▲(16.09% Upside)
Action:ReiteratedDate:03/10/26
The score is driven primarily by improving financial performance (profitability and cash flow rebounding with manageable leverage), supported by a positive earnings outlook and margin-expansion guidance. This is tempered by mixed near-term technical signals and only moderate valuation support (modest dividend yield), alongside stated pricing and one-off cost headwinds.
Positive Factors
Biosimilars Momentum
Biosimilars reaching ~30% of sales and showing double‑digit growth shifts revenue toward higher‑margin biologics. That improves revenue quality and reduces dependence on commoditized generics. Coupled with the Just‑Evotec acquisition and a Slovenia hub, it strengthens development and manufacturing scale advantages for durable competitive positioning.
Margin Resilience
Sandoz's sustained gross margins in the mid/high‑40s and a core EBITDA margin increase to ~21.7% reflect structural cost efficiency and favorable product mix. Stable gross margins provide operating leverage, supporting durable profitability even with volume swings and enabling reinvestment in pipeline and manufacturing to preserve margin over time.
Improved Cash & Leverage
A meaningful jump in free cash flow to ~$1.5bn and net debt/EBITDA near ~1.5x materially strengthens financial flexibility. This durable cash generation supports peak biosimilars CapEx (~$1.1bn), integration of acquisitions, and capital discipline without excessive leverage, improving resiliency across cycles (noting reported FX noise).
Negative Factors
Price Erosion
Persistent low‑to‑mid single‑digit price erosion is a structural pressure in generics markets. Over time this compresses unit revenues and limits margin expansion unless offset by higher‑margin mix or sustained cost reductions. It forces continuous efficiency gains or strategic shift toward biosimilars to maintain long‑run profitability.
Penicillin API Disruption
Aggressive API dumping and market distortion in penicillin indicate durable supply‑side volatility for essential antibiotics. Such structural disruptions can depress realized sales value, force price concessions, and create recurring revenue volatility in that portfolio, limiting predictability and raising the need for strategic sourcing or portfolio shifts.
Regulatory / IP Risk
Complex patent landscapes, unpredictable regulatory outcomes, and sporadic injunctions create structural timing and access risk for biosimilars. These legal and regulatory uncertainties can materially delay revenue recognition from launches, increase litigation and compliance costs, and extend payback periods on R&D and heavy manufacturing investments.
Sandoz Group Ltd Sponsored ADR (SDZNY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$34.95B
Dividend Yield0.98%
Average Volume (3M)13.20K
Price to Earnings (P/E)18.4
Beta (1Y)0.47
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees22,049
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.24
Shares Outstanding440,000,000
10 Day Avg. Volume3,665
30 Day Avg. Volume13,196
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.34
Price to Sales (P/S)3.55
P/FCF Ratio38.74
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue4.38
Enterprise Value/Gross Profit9.28
Enterprise Value/Ebitda26.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sandoz Group Ltd Sponsored ADR Business Overview & Revenue Model
Company DescriptionSandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
How the Company Makes MoneySandoz generates revenue primarily through the sale of its generic drugs and biosimilars. The company's revenue model is based on pricing strategies that allow for competitive pricing against branded counterparts while maintaining margins. Key revenue streams include the direct sales of generic pharmaceuticals to wholesalers, pharmacies, and healthcare providers, as well as sales of biosimilars that offer cost-effective alternatives to expensive biologic treatments. Additionally, Sandoz benefits from strategic partnerships with healthcare systems and collaborations with other pharmaceutical companies for the development and commercialization of new products. The global trend towards increased acceptance of generics and biosimilars, driven by healthcare cost containment efforts, significantly contributes to Sandoz's earnings.
Sandoz Group Ltd Sponsored ADR Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call presented a strongly positive operational and financial performance with multiple clear achievements: revenue exceeded $11 billion, biosimilars gained share and drove margin expansion, cash generation and EPS improved materially, and strategic investments (Just-Evotec acquisition and a Slovenian biosimilars hub) position the company for future growth. Notable near-term headwinds include penicillin B2B price disruption, ongoing low- to mid-single-digit price erosion, FX impacts on reported net debt, one-off integration and IT costs, and regulatory/IP uncertainties (especially in the U.S.) that could affect timing and scale of some opportunities. On balance, the highlights (broad-based sales growth, margin expansion, strong cash flow, successful launches, strengthened pipeline and manufacturing investments) outweigh the lowlights, which are significant but largely manageable and either transient or being mitigated through strategic actions.Q4-2025 Updates
Positive Updates
Record Annual Net Sales Above $11 Billion
Net sales surpassed $11.0 billion for the first time, reported at $11.1 billion with growth of ~5% at constant currencies (Remco cited underlying growth of 6%). Q4 marked the 17th consecutive quarter of sales growth.
Strong Biosimilars Momentum and Mix Shift
Biosimilars grew strongly (Richard cited 13% growth; Remco noted 18% underlying biosimilars growth) and now represent ~30% of total net sales (31% in Q4). Biosimilars contributed meaningfully to mix, driving margin expansion.
Margin Expansion and Profitability
Core EBITDA margin expanded by 160 basis points to 21.7% (from 20.1%), with core EBITDA up ~14% year-on-year. Core gross profit reached $5.6 billion with a gross margin of 50.6%.
Strong EPS and Cash Generation
Core diluted EPS grew by 33%. Management free cash flow increased by $435 million to $1.5 billion, reflecting improved operating performance and working capital discipline.
Improved Return on Invested Capital and Leverage
Core ROIC improved to 14.5% (up ~2.0–2.2 percentage points). Net debt-to-core-EBITDA improved to ~1.5x; underlying net debt (ex-FX) fell by $200 million to ~$3.1 billion (reported net debt $3.6 billion affected by FX).
Successful New Product Launches
Multiple launches: Pyzchiva (U.S. and EU auto-injector), Tyruko (EU and U.S. roll-out), Wyost and Jubbonti (first denosumab biosimilars in the U.S. and launches in EU/Canada), Afqlir (entered Europe; U.S. launch expected Q4 2026), and Enzeevu label expansion by the FDA—all positioned to contribute meaningful growth.
Strategic Acquisition and Manufacturing Investment
Acquisition of Just-Evotec Biologics Europe completed end-2025 to strengthen biologics development and continuous manufacturing capability. Investing to build an end-to-end biosimilars hub in Slovenia; CapEx ~ $700 million in 2025 and expected ~ $1.1 billion in 2026 (peak year) primarily for biosimilar capabilities.
Broad Regional Performance and Diversification
Performance was broad-based: Europe 54% of net sales and grew ~6%; International ~24% (underlying +9% for year, +14% in Q4); North America ~22% (underlying +5% for year). Volumes contributed +8% to sales, FX +2% and price erosion moderate at -3%.
Sustainability and Access Impact
Served over 1 billion patients in >100 countries and delivered $26 billion in savings to health-care systems. Emissions reductions: Scope 1 down 18%, Scope 2 down 15%, Scope 3 down 1%. SBTi targets submitted for validation.
Negative Updates
Penicillin B2B Business Disruption
Adverse impact from Asian suppliers' aggressive price dumping for key penicillin APIs reduced sales value in H2 2025; management expects these adverse dynamics to persist into H1 2026 and notes potential market distortions from India minimum import price changes.
Ongoing Price Erosion and Competitive Pressure
Price erosion remained a headwind (-3% in 2025) and management expects continued low- to mid-single-digit price erosion in 2026. Denosumab faces upcoming competitor entries that could pressure pricing despite a strong initial launch.
Foreign Exchange Headwind on Reported Net Debt
Reported net debt increased to $3.6 billion due to a stronger euro and Swiss franc versus the U.S. dollar; underlying net debt excluding FX improved by $200 million to $3.1 billion, indicating FX materially impacted reported leverage.
One-Off and IT Implementation Costs
One-off costs declined to ~$0.4 billion in 2025 and are forecast at ~ $0.3 billion in 2026 (combined ~$0.7 billion as expected). Software/IT implementation costs (~$50 million in 2025 and similar in 2026) cannot be capitalized under SaaS accounting, representing an incremental non-capex expense.
Regulatory/IP Uncertainty in Key Markets
U.S. regulatory and IP unpredictability (e.g., complex patent situations for some originators like Keytruda/semaglutide and historical extended patent tactics such as the Amgen Enbrel situation) remain a risk to timing and scale of U.S. biosimilar rollouts.
Market Uncertainty for GLP-1s
GLP-1 opportunity described as long-term with uncertain near-term contribution; launch timing depends on regulatory approvals (Canada/Brazil filings pending) and unclear demand/volume dynamics and supply constraints in markets like India could complicate strategy and forecasting.
Integration Costs Related to Acquisition
Planned one-off integration costs for the Just-Evotec business in France in 2026 will weigh on near-term results and are included in guidance as a one-off expense.
Localized Legal and Market Obstacles
Recent injunctions / court disputes (e.g., aflibercept in Germany previously affected by court actions) create intermittently blocked market access and legal risk, although some injunctions were recently reversed.
Company Guidance
Sandoz guided 2026 net sales to grow mid‑ to high‑single‑digit percentage in constant currencies (with an estimated ~2 percentage‑point currency tailwind based on recent spot/Jan‑2026 rates) and targeted about a 100 basis‑point expansion in core EBITDA margin versus 2025’s 21.7% (implying ≈22.7%), while expecting price erosion of low‑ to mid‑single‑digit percent; they warned the penicillin B2B headwind should persist in H1 2026 and flagged a one‑off Just‑Evotec integration cost in France, forecast CapEx of ~USD 1.1bn (peak year, mainly for biosimilars), one‑off costs of ~USD 0.3bn in 2026 (USD 0.7bn combined for 2025–26), and roughly USD 50m of software (SaaS) implementation costs likely again in 2026, with no material FX impact expected on the core EBITDA margin.Sandoz Group Ltd Sponsored ADR Financial Statement Overview
Summary
Financials show a clear 2025 rebound in profitability and cash generation, with resilient gross margins and manageable recent leverage. Offsetting this, revenue growth has been uneven and earnings/free cash flow have been volatile year-to-year, with some historical comparability noise (notably 2022 equity anomaly).Income Statement
Profitability rebounded meaningfully in 2025 as operating profit and net income recovered to solid levels (net margin ~8% vs. near breakeven in 2024). Gross margin has remained steady in the mid‑to‑high 40% range, supporting a stable earnings base for a specialty/generics business. The key weakness is uneven growth: revenue fell in 2025 after modest growth in 2024, and results show volatility versus the stronger 2021–2022 period.62
Positive
Balance Sheet
Leverage looks manageable in recent years, with debt-to-equity around ~0.6 in 2023–2025 and equity expanding from 2024 to 2025, suggesting improving balance-sheet capacity. Returns to shareholders improved in 2025 versus 2023–2024, consistent with the earnings rebound. The main concern is data instability in 2022 (abnormally low equity leading to extreme leverage/return figures), which raises comparability risk across the full history, although the 2023–2025 profile appears much more normalized.66
Positive
Cash Flow
Cash generation improved sharply in 2025 with higher operating cash flow and a strong jump in free cash flow (positive and materially higher than 2024), aligning better with improved earnings. However, cash conversion is not consistently strong across the period: free cash flow was negative in 2023, and the share of earnings translating into free cash flow is moderate in 2025 (roughly half). Overall, cash flow is trending better but remains somewhat volatile year-to-year.60
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.84B | 10.38B | 9.98B | 8.60B | 8.79B |
| Gross Profit | 4.16B | 4.93B | 4.56B | 4.05B | 4.15B |
| EBITDA | 1.36B | 742.00M | 857.00M | 1.53B | 1.67B |
| Net Income | 728.65M | 1.00M | 77.00M | 784.05M | 830.15M |
Balance Sheet | |||||
| Total Assets | 22.03B | 19.91B | 19.43B | 16.23B | 15.98B |
| Cash, Cash Equivalents and Short-Term Investments | 1.74B | 1.19B | 1.11B | 74.00M | 36.45M |
| Total Debt | 5.68B | 4.85B | 4.55B | 3.87B | 4.51B |
| Total Liabilities | 12.65B | 11.74B | 10.78B | 22.86K | 8.55B |
| Stockholders Equity | 9.38B | 8.16B | 8.64B | 77.14K | 7.43B |
Cash Flow | |||||
| Free Cash Flow | 810.00M | 60.00M | -263.00M | 760.23M | 855.75M |
| Operating Cash Flow | 1.59B | 656.00M | 362.00M | 1.17B | 1.24B |
| Investing Cash Flow | -980.00M | -740.00M | -614.00M | -430.00M | -631.76M |
| Financing Cash Flow | -197.00M | 242.00M | 1.24B | -769.00M | -600.67M |
Sandoz Group Ltd Sponsored ADR Technical Analysis
Neutral
75.80
Price Trends
80.83
Negative
75.05
Positive
66.40
Positive
Market Momentum
-0.70
Positive
43.04
Neutral
5.74
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SDZNY, the sentiment is Neutral. The current price of 75.8 is below the 20-day moving average (MA) of 84.39, below the 50-day MA of 80.83, and above the 200-day MA of 66.40, indicating a neutral trend. The MACD of -0.70 indicates Positive momentum. The RSI at 43.04 is Neutral, neither overbought nor oversold. The STOCH value of 5.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SDZNY.
Sandoz Group Ltd Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $11.52B | 21.72 | 16.00% | 0.64% | 10.63% | 6.35% | |
64 Neutral | $34.95B | 18.41 | 10.09% | 0.98% | ― | ― | |
61 Neutral | $33.94B | 25.43 | 20.09% | ― | -0.25% | ― | |
61 Neutral | $57.04B | 18.30 | 1.58% | 3.86% | -1.98% | -86.20% | |
56 Neutral | $15.56B | -4.15 | -22.99% | 3.99% | -6.40% | -320.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.34B | -1.35 | -35.16% | 8.48% | -2.55% | 66.00% |
* Healthcare Sector Average
SDZNY
Sandoz Group Ltd Sponsored ADR
80.05
38.06
90.62%
RDY
Dr Reddy's Laboratories
14.19
0.82
6.11%
VTRS
Viatris
13.80
4.80
53.33%
PRGO
Perrigo Company
10.30
-15.77
-60.49%
TEVA
Teva Pharmaceutical
30.09
13.80
84.71%
TAK
Takeda Pharmaceutical Company
18.39
3.58
24.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.